Literature DB >> 16612257

The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients.

Timothy W Doulton1, Anand K Saggar-Malik, Feng J He, Christine Carney, Nirmala D Markandu, Guiseppe A Sagnella, Graham A MacGregor.   

Abstract

BACKGROUND: It has been suggested that inappropriate stimulation of the renin-angiotensin system (RAS) is responsible for the increase in blood pressure that occurs in autosomal-dominant polycystic kidney disease (ADPKD) before the development of renal failure. However, the interpretation of previous studies in ADPKD patients is confounded by inadequate matching with control populations for blood pressure and renal function, or failure to control the sodium intake of participants.
METHODS: A double-blind, placebo-controlled study of two different sodium intakes (350 and 50 mmol/day for 5 days) in a group of 11 hypertensive ADPKD patients and eight matched control subjects with essential hypertension. In addition, blood pressure and hormonal responses were measured after the administration of the angiotensin-converting enzyme inhibitor enalapril for 3 days.
RESULTS: Blood pressure and hormonal responses of the RAS after a reduction in sodium intake and after the administration of enalapril were identical in ADPKD patients and controls.
CONCLUSIONS: Activation of the classic circulating RAS is no greater in hypertensive ADPKD patients than in individuals with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612257     DOI: 10.1097/01.hjh.0000222765.30348.0d

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 2.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

Review 3.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

4.  Polycystic kidneys have decreased vascular density: a micro-CT study.

Authors:  Rende Xu; Federico Franchi; Brent Miller; John A Crane; Karen M Peterson; Peter J Psaltis; Peter C Harris; Lilach O Lerman; Martin Rodriguez-Porcel
Journal:  Microcirculation       Date:  2013-02       Impact factor: 2.628

5.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

Review 6.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

Review 7.  The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.

Authors:  Bharathi V Reddy; Arlene B Chapman
Journal:  Pediatr Nephrol       Date:  2016-03-31       Impact factor: 3.714

Review 8.  Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.

Authors:  Dana Rizk; Arlene Chapman
Journal:  Pediatr Nephrol       Date:  2008-02-08       Impact factor: 3.714

Review 9.  Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Marinella Ruospo; Carmine Zoccali; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

10.  Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study.

Authors:  Hayne Cho Park; Jin Ho Hwang; Ah-Young Kang; Han Ro; Myung-Gyu Kim; Jung Nam An; Ji In Park; Seung Hyup Kim; Jaeseok Yang; Yun Kyu Oh; Kook-Hwan Oh; Jung Woo Noh; Hae Il Cheong; Young-Hwan Hwang; Curie Ahn
Journal:  BMC Nephrol       Date:  2012-08-30       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.